scholarly journals CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women

2007 ◽  
Vol 13 (4) ◽  
pp. 231-236 ◽  
Author(s):  
M. Henningson ◽  
U. Johansson ◽  
Å. Borg ◽  
H. Olsson ◽  
Helena Jernström
Keyword(s):  
Oral Contraceptive ◽  
Contraceptive Use ◽  
Brca Mutation ◽  
Mutation Status ◽  
Menstrual Cycles ◽  
Healthy Women ◽  
Oral Contraceptive Use

Oral contraceptive use and saliva diurnal pattern of metabolic steroid hormones in young healthy women

Contraception ◽  
2015 ◽  
Vol 91 (3) ◽  
pp. 245-247 ◽  
Author(s):  
N. Vibarel-Rebot ◽  
N. Rieth ◽  
F. Lasne ◽  
C. Jaffré ◽  
K. Collomp
Keyword(s):  
Oral Contraceptive ◽  
Steroid Hormones ◽  
Contraceptive Use ◽  
Diurnal Pattern ◽  
Healthy Women ◽  
Oral Contraceptive Use

scholarly journals Development of a Novel Immunoassay for the Assessment of Plasma Gas6 Concentrations and Their Variation with Hormonal Status

2007 ◽  
Vol 53 (10) ◽  
pp. 1808-1813 ◽  
Author(s):  
Sylvain Clauser ◽  
Séverine Peyrard ◽  
Pascale Gaussem ◽  
Malvina Crespin ◽  
Joseph Emmerich ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Contraceptive Use ◽  
Plasma Concentrations ◽  
Hormonal Status ◽  
Elisa Assay ◽  
Menstrual Cycles ◽  
Oral Contraceptive Use ◽  
Development And Validation ◽  
Time Point

Abstract Background: Gas6 is a vitamin K–dependent antiapoptotic protein that has been implicated in cardiovascular pathophysiology. We report the development and validation of an ELISA for Gas6, and the variation of plasma Gas6 with hormonal status in a study designed to evaluate the effect of oral contraception on plasma markers. Methods: After validation of the main stages of the ELISA assay, we measured plasma Gas6 concentrations in 94 male and 88 female healthy volunteers ages 18 to 38 years. Forty-five of the women then received an oral contraceptive, which contained ethinylestradiol and levonorgestrel, for 3 months before a new measurement was performed at the same time point in their menstrual cycles. Results: Interassay imprecision was 5.8%–11.8%, and the detection limit was 5.9 μg/L. Mean Gas6 plasma concentrations were significantly lower in men (52.0 μg/L) than in women not receiving oral contraceptives (63.8 μg/L, P <0.001). In the women who received oral contraceptives, Gas6 concentrations decreased after 3 months of therapy from 63.6 μg/L to 51.9 μg/L (P <0.001). Conclusions: We have developed a simple and reproducible ELISA assay for measuring plasma Gas6 concentrations, which vary with sex and are decreased by oral contraceptive use. These results suggest regulation of plasma Gas6 concentrations by sex hormones. Future clinical studies may require participants to be stratified by sex.

Maximal fat oxidation, but not aerobic capacity, is affected by oral contraceptive use in young healthy women

2014 ◽  
Vol 115 (5) ◽  
pp. 937-945 ◽  
Author(s):  
Laurie Isacco ◽  
David Thivel ◽  
Bruno Pereira ◽  
Martine Duclos ◽  
Nathalie Boisseau
Keyword(s):  
Oral Contraceptive ◽  
Aerobic Capacity ◽  
Contraceptive Use ◽  
Fat Oxidation ◽  
Healthy Women ◽  
Oral Contraceptive Use ◽  
Maximal Fat Oxidation

scholarly journals Oral contraceptive use, iron stores and vascular endothelial function in healthy women

Contraception ◽  
2011 ◽  
Vol 84 (3) ◽  
pp. 285-290 ◽  
Author(s):  
Julie Friedman ◽  
Miriam Cremer ◽  
Qurat ul-ain Jelani ◽  
Xi Huang ◽  
Jinlong Jian ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Endothelial Function ◽  
Contraceptive Use ◽  
Vascular Endothelial ◽  
Vascular Endothelial Function ◽  
Iron Stores ◽  
Healthy Women ◽  
Oral Contraceptive Use

Free norethisterone as reflected by saliva concentrations of norethisterone during oral contraceptive use

1981 ◽  
Vol 98 (3) ◽  
pp. 470-476 ◽  
Author(s):  
Viveca Odlind ◽  
Elof D. B. Johansson
Keyword(s):  
Oral Contraceptive ◽  
Contraceptive Use ◽  
Equilibrium Dialysis ◽  
Plasma Concentrations ◽  
Free Fraction ◽  
Sex Hormone Binding Globulin ◽  
Total Plasma ◽  
Healthy Women ◽  
Oral Contraceptive Use ◽  
Epileptic Woman

Abstract. Saliva and plasma concentrations of norethisterone (NET) were determined by a radioimmunoassay in 5 healthy women and in one epileptic woman on phenytoin treatment during a 21-day cycle on an oral contraceptive containing 3 mg NET-acetate and 0.05 mg ethinyloestradiol. Plasma non-protein bound concentrations of NET were determined by equilibrium dialysis. Sex hormone binding globulin (SHBG) was measured in all samples. An excellent correlation was found between plasma total, plasma non-protein bound and saliva levels of NET. Plasma non-protein bound and saliva concentrations were in the same range throughout, indicating that saliva concentrations reflect the free fraction of NET in plasma. SHBG increased considerably in all women. A slight decrease in the ratio between total and non-protein bound concentrations was found with time, possibly reflecting a slight increase in protein binding with increasing SHBG. The woman on anticonvulsant therapy had plasma total, plasma unbound and saliva NET concentrations that were only 30 per cent of those of the healthy women. The relationship between the different fractions was similar to that found in the healthy women. The non-protein bound fraction of NET was 4–5 per cent of the total in all women studied.

Sign in / Sign up

Export Citation Format

Share Document